Evolving field of cardio-oncology

Area of Science:

• Cardio-oncology
• Translational medicine
• Drug metabolism and transport

Background:

• Therapy development for cancer and cardiovascular disease (CVD) prolongs lifespan, increasing complexity in their interrelationship.
• Drug interactions are a significant concern in both cardiology and oncology, involving metabolism and drug transportation pathways.
• Cardiotoxicity detection has advanced with novel biomarkers and imaging techniques, identifying cardiac injury and inflammation.

Purpose of the Study:

• To explore the complex interplay between cancer therapies, cardiovascular disease, and cancer risk.
• To highlight advancements in detecting and managing cardiotoxicity.
• To introduce the emerging concept of "reverse cardio-oncology".

Main Methods:

• Review of current literature on drug interactions in oncology and cardiology.
• Analysis of advancements in biomarker and imaging technologies for cardiotoxicity detection.
• Conceptual framework development for CVD-related cancer risk and reverse cardio-oncology.

Main Results:

• Therapy-induced cardiotoxicity and drug interactions represent significant challenges.
• Biomarkers and imaging offer improved detection of cardiac adverse events.
• Cardiovascular disease is increasingly recognized as a risk factor for cancer development.

Conclusions:

• The intersection of cancer and CVD requires integrated management strategies.
• Early detection and monitoring of cardiotoxicity are crucial for patient outcomes.
• The concept of reverse cardio-oncology opens new avenues for research and clinical practice.